Literature DB >> 30548501

A quantitative LC-MS/MS method for determination of a small molecule agonist of EphA2 in mouse plasma and brain tissue.

Bo Zhong1, Yaxin Li1, Nethrie Idippily1, Aaron Petty2,3, Bin Su1, Bingcheng Wang2,3.   

Abstract

Compound 27 {1, 12-bis[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]dodecane-1,12-dione} is a novel small molecule agonist of EphA2 receptor tyrosine kinase. It showed much improved activity for the activation of EphA2 receptor compared with the parental compound doxazosin. To support further pharmacological and toxicological studies of the compound, a method using liquid chromatography and electrospray ionization tandem mass spectrometry (LC-MS/MS) has been developed for the quantification of this compound. Liquid-liquid extraction was used to extract the compound from mouse plasma and brain tissue homogenate. Reverse-phase chromatography with gradient elution was performed to separate compound 27 from the endogenous molecules in the matrix, followed by MS detection using positive ion multiple reaction monitoring mode. Multiple reaction monitoring transitions m/z 387.3 → 290.1 and m/z 384.1 → 247.1 were selected for monitoring compound 27 and internal standard prazosin, respectively. The linear calibration range was 2-200 ng/mL with the intra- and inter-day precision and accuracy within the acceptable range. This method was successfully applied to the quantitative analysis of compound 27 in mouse plasma and brain tissue with different drug administration routes.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  EphA2; LC-MS/MS; agonist; cancer; pharmacokinetics

Mesh:

Substances:

Year:  2019        PMID: 30548501      PMCID: PMC6416057          DOI: 10.1002/bmc.4461

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  16 in total

1.  Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells.

Authors:  Jonathan W Astin; Jennifer Batson; Shereen Kadir; Jessica Charlet; Raj A Persad; David Gillatt; Jon D Oxley; Catherine D Nobes
Journal:  Nat Cell Biol       Date:  2010-11-14       Impact factor: 28.824

Review 2.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 3.  Eph-ephrin bidirectional signaling in physiology and disease.

Authors:  Elena B Pasquale
Journal:  Cell       Date:  2008-04-04       Impact factor: 41.582

4.  Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.

Authors:  Xia Li; Li Wang; Jian-Wen Gu; Bing Li; Wei-Ping Liu; Yan-Gang Wang; Xiang Zhang; Hai-Ning Zhen; Zhou Fei
Journal:  Tumour Biol       Date:  2010-06-23

Review 5.  Ephrin expression and function in cancer.

Authors:  Jennifer K McCarron; Brett W Stringer; Bryan W Day; Andrew W Boyd
Journal:  Future Oncol       Date:  2010-01       Impact factor: 3.404

6.  Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.

Authors:  Kelly Carles-Kinch; Katherine E Kilpatrick; Jane C Stewart; Michael S Kinch
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

7.  Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.

Authors:  Mark S Duxbury; Hiromichi Ito; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Biochem Biophys Res Commun       Date:  2004-08-06       Impact factor: 3.575

8.  Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.

Authors:  Loren W Noblitt; Dinesh S Bangari; Shruti Shukla; Deborah W Knapp; Sulma Mohammed; Michael S Kinch; Suresh K Mittal
Journal:  Cancer Gene Ther       Date:  2004-11       Impact factor: 5.987

9.  EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.

Authors:  Hui Miao; Da-Qiang Li; Amitava Mukherjee; Hong Guo; Aaron Petty; Jennifer Cutter; James P Basilion; John Sedor; Jiong Wu; David Danielpour; Andrew E Sloan; Mark L Cohen; Bingcheng Wang
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

10.  A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.

Authors:  Dowdy Jackson; John Gooya; Shenlan Mao; Krista Kinneer; Linda Xu; Margarita Camara; Christine Fazenbaker; Ryan Fleming; Sudha Swamynathan; Damon Meyer; Peter D Senter; Changshou Gao; Herren Wu; Michael Kinch; Steven Coats; Peter A Kiener; David A Tice
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

View more
  1 in total

1.  Dimeric small molecule agonists of EphA2 receptor inhibit glioblastoma cell growth.

Authors:  Cody M Orahoske; Yaxin Li; Aaron Petty; Fatma M Salem; Jovana Hanna; Wenjing Zhang; Bin Su; Bingcheng Wang
Journal:  Bioorg Med Chem       Date:  2020-07-25       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.